MicroRNA genes and their target 3′-untranslated regions are infrequently somatically mutated in ovarian cancers

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Ryland, Georgina L ^a,b   Bearfoot, Jennifer L ^a,c   Doyle, Maria A ^a   Boyle, Samantha E ^a   Choong, David Y H ^a   Rowley, Simone M ^a   Tothill, Richard W ^a   Gorringe, Kylie L ^a,c   Campbell, Ian G ^a,c  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; AKT2 PROTEIN, HUMAN; BETA CATENIN; CTNNB1 PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; PROTEIN KINASE B;

3' UNTRANSLATED REGION; ARTICLE; BINDING SITE; CONTROLLED STUDY; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENE MUTATION; GENE SEQUENCE; GENE STRUCTURE; GENE TARGETING; HUMAN; HUMAN TISSUE; NUCLEOTIDE SEQUENCE; ONCOGENE; ONCOGENE AKT2; ONCOGENE CTNNB1; ONCOGENE EGFR; ONCOGENE ERRB2; OVARY CANCER; SOMATIC MUTATION; GENETIC ASSOCIATION; GENETICS; MUTATION; OVARY TUMOR;

3' UNTRANSLATED REGIONS; BETA CATENIN; BINDING SITES; DNA MUTATIONAL ANALYSIS; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; MICRORNAS; MUTATION; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2;

EID: 84859977224     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0035805     Document Type: Article

References (51)

1. Bartel DP, (2004) Micrornas: Genomics, biogenesis, mechanism, and function. Cell 116: 281-297.
2. Bartel DP, (2009) Micrornas: Target recognition and regulatory functions. Cell 136: 215-233.
3. Rajewsky N, (2006) Microrna target predictions in animals. Nat Genet 38 (Suppl): S8-13.
4. Lytle JR, Yario TA, Steitz JA, (2007) Target mrnas are repressed as efficiently by microrna-binding sites in the 5′ utr as in the 3′ utr. Proc Natl Acad Sci U S A 104: 9667-9672.
5. Lee I, Ajay SS, Yook JI, Kim HS, Hong SH, et al. (2009) New class of microrna targets containing simultaneous 5′-utr and 3′-utr interaction sites. Genome Res 19: 1175-1183.
6. Tay Y, Zhang J, Thomson AM, Lim B, Rigoutsos I, (2008) Micrornas to nanog, oct4 and sox2 coding regions modulate embryonic stem cell differentiation. Nature 455: 1124-1128.
7. Calin GA, Croce CM, (2006) Microrna signatures in human cancers. Nat Rev Cancer 6: 857-866.
8. Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, et al. (2005) A microrna signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 353: 1793-1801.
9. Zhang L, Huang J, Yang N, Greshock J, Megraw MS, et al. (2006) Micrornas exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci U S A 103: 9136-9141.
10. Zhang L, Volinia S, Bonome T, Calin GA, Greshock J, et al. (2008) Genomic and epigenetic alterations deregulate microrna expression in human epithelial ovarian cancer. Proc Natl Acad Sci U S A 105: 7004-7009.
11. Ryan BM, Robles AI, Harris CC, (2010) Genetic variation in microrna networks: The implications for cancer research. Nat Rev Cancer 10: 389-402.
12. Diederichs S, Haber DA, (2006) Sequence variations of micrornas in human cancer: Alterations in predicted secondary structure do not affect processing. Cancer Res 66: 6097-6104.
13. Ramsingh G, Koboldt DC, Trissal M, Chiappinelli KB, Wylie T, et al. (2010) Complete characterization of the micrornaome in a patient with acute myeloid leukemia. Blood 116: 5316-5326.
14. Wu M, Jolicoeur N, Li Z, Zhang L, Fortin Y, et al. (2008) Genetic variations of micrornas in human cancer and their effects on the expression of mirnas. Carcinogenesis 29: 1710-1716.
15. Ratner E, Lu L, Boeke M, Barnett R, Nallur S, et al. (2010) A kras-variant in ovarian cancer acts as a genetic marker of cancer risk. Cancer Res 70: 6509-6515.
16. Wynendaele J, Bohnke A, Leucci E, Nielsen SJ, Lambertz I, et al. (2010) An illegitimate microrna target site within the 3′ utr of mdm4 affects ovarian cancer progression and chemosensitivity. Cancer Res 70: 9641-9649.
17. Chin LJ, Ratner E, Leng S, Zhai R, Nallur S, et al. (2008) A snp in a let-7 microrna complementary site in the kras 3′ untranslated region increases non-small cell lung cancer risk. Cancer Res 68: 8535-8540.
18. Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, et al. (2007) Microrna signatures in human ovarian cancer. Cancer Res 67: 8699-8707.
19. Wyman SK, Parkin RK, Mitchell PS, Fritz BR, O'Briant K, et al. (2009) Repertoire of micrornas in epithelial ovarian cancer as determined by next generation sequencing of small rna cdna libraries. PLoS One 4: e5311.
20. Yang H, Kong W, He L, Zhao JJ, O'Donnell JD, et al. (2008) Microrna expression profiling in human ovarian cancer: Mir-214 induces cell survival and cisplatin resistance by targeting pten. Cancer Res 68: 425-433.
21. Nam EJ, Yoon H, Kim SW, Kim H, Kim YT, et al. (2008) Microrna expression profiles in serous ovarian carcinoma. Clin Cancer Res 14: 2690-2695.
22. Dahiya N, Sherman-Baust CA, Wang TL, Davidson B, Shih Ie M, et al. (2008) Microrna expression and identification of putative mirna targets in ovarian cancer. PLoS One 3: e2436.
23. The Cancer Genome Atlas Research Network (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474: 609-615.
24. Bearfoot JL, Choong DY, Gorringe KL, Campbell IG, (2008) Genetic analysis of cancer-implicated microrna in ovarian cancer. Clin Cancer Res 14: 7246-7250.
25. Yang J, Zhou F, Xu T, Deng H, Ge YY, et al. (2008) Analysis of sequence variations in 59 micrornas in hepatocellular carcinomas. Mutat Res 638: 205-209.
26. Kim VN, (2005) Microrna biogenesis: Coordinated cropping and dicing. Nat Rev Mol Cell Biol 6: 376-385.
27. Gruber AR, Lorenz R, Bernhart SH, Neubock R, Hofacker IL, (2008) The vienna rna websuite. Nucleic Acids Res 36: W70-74.
28. Guttilla IK, White BA, (2009) Coordinate regulation of foxo1 by mir-27a, mir-96, and mir-182 in breast cancer cells. J Biol Chem 284: 23204-23216.
29. van Kouwenhove M, Kedde M, Agami R, (2011) Microrna regulation by rna-binding proteins and its implications for cancer. Nat Rev Cancer.
30. Melo SA, Esteller M, (2011) A precursor microrna in a cancer cell nucleus: Get me out of here! Cell Cycle 10: 922-925.
31. Merritt WM, Lin YG, Han LY, Kamat AA, Spannuth WA, et al. (2008) Dicer, drosha, and outcomes in patients with ovarian cancer. N Engl J Med 359: 2641-2650.
32. Futreal PA, Coin L, Marshall M, Down T, Hubbard T, et al. (2004) A census of human cancer genes. Nat Rev Cancer 4: 177-183.
33. Birrer MJ, Johnson ME, Hao K, Wong KK, Park DC, et al. (2007) Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas. J Clin Oncol 25: 2281-2287.
34. Sheach LA, Adeney EM, Kucukmetin A, Wilkinson SJ, Fisher AD, et al. (2009) Androgen-related expression of g-proteins in ovarian cancer. Br J Cancer 101: 498-503.
35. Cheng KW, Lahad JP, Kuo WL, Lapuk A, Yamada K, et al. (2004) The rab25 small gtpase determines aggressiveness of ovarian and breast cancers. Nat Med 10: 1251-1256.
36. Yiu GK, Chan WY, Ng SW, Chan PS, Cheung KK, et al. (2001) Sparc (secreted protein acidic and rich in cysteine) induces apoptosis in ovarian cancer cells. Am J Pathol 159: 609-622.
37. Said N, Najwer I, Motamed K, (2007) Secreted protein acidic and rich in cysteine (sparc) inhibits integrin-mediated adhesion and growth factor-dependent survival signaling in ovarian cancer. Am J Pathol 170: 1054-1063.
38. Grimson A, Farh KK, Johnston WK, Garrett-Engele P, Lim LP, et al. (2007) Microrna targeting specificity in mammals: Determinants beyond seed pairing. Mol Cell 27: 91-105.
39. Bryan EJ, Watson RH, Davis M, Hitchcock A, Foulkes WD, et al. (1996) Localization of an ovarian cancer tumor suppressor gene to a 0.5-cm region between d22s284 and cyp2d, on chromosome 22q. Cancer Res 56: 719-721.
40. Griffiths-Jones S, Saini HK, van Dongen S, Enright AJ, (2008) Mirbase: Tools for microrna genomics. Nucleic Acids Res 36: D154-158.
41. Kozomara A, Griffiths-Jones S, (2011) Mirbase: Integrating microrna annotation and deep-sequencing data. Nucleic Acids Res 39: D152-157.
42. Novocraft Technologies.
43. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, et al. (2010) The genome analysis toolkit: A mapreduce framework for analyzing next-generation DNA sequencing data. Genome Res 20: 1297-1303.
44. Albers CA, Lunter G, Macarthur DG, McVean G, Ouwehand WH, et al. (2010) Dindel: Accurate indel calls from short-read data. Genome Res.
45. Robinson JT, Thorvaldsdottir H, Winckler W, Guttman M, Lander ES, et al. (2011) Integrative genomics viewer. Nat Biotechnol 29: 24-26.
46. Friedman RC, Farh KK, Burge CB, Bartel DP, (2009) Most mammalian mrnas are conserved targets of micrornas. Genome Res 19: 92-105.
47. Maragkakis M, Alexiou P, Papadopoulos GL, Reczko M, Dalamagas T, et al. (2009) Accurate microrna target prediction correlates with protein repression levels. BMC Bioinformatics 10: 295.
48. Maragkakis M, Reczko M, Simossis VA, Alexiou P, Papadopoulos GL, et al. (2009) Diana-microt web server: Elucidating microrna functions through target prediction. Nucleic Acids Res 37: W273-276.
49. Betel D, Wilson M, Gabow A, Marks DS, Sander C, (2008) The microrna.Org resource: Targets and expression. Nucleic Acids Res 36: D149-153.
50. Tothill RW, Tinker AV, George J, Brown R, Fox SB, et al. (2008) Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 14: 5198-5208.
51. Ramakrishna M, Williams LH, Boyle SE, Bearfoot JL, Sridhar A, et al. (2011) Identification of candidate growth promoting genes in ovarian cancer through integrated copy number and expression analysis. PLoS One 5: e9983.